| Autor: |
Bewersdorf, Jan Philipp, Patel, Kishan K., Shallis, Rory M., Podoltsev, Nikolai A., Kewan, Tariq, Stempel, Jessica, Mendez, Lourdes, Stahl, Maximilian, Stein, Eytan M., Huntington, Scott F., Goshua, George, Zeidan, Amer M. |
| Předmět: |
|
| Zdroj: |
Leukemia & Lymphoma; Aug2024, Vol. 65 Issue 8, p1136-1144, 9p |
| Abstrakt: |
The FLT3 inhibitor quizartinib has been shown to improve overall survival when added to intensive induction chemotherapy ("7 + 3") in patients 18-75 years old with newly diagnosed AML harboring a FLT3-ITD mutation. However, the health economic implications of this approval are unknown. We evaluated the cost-effectiveness of quizartinib using a partitioned survival analysis model. One-way and probabilistic sensitivity analyses were conducted. In the base case scenario, the addition of quizartinib to 7 + 3 resulted in incremental costs of $289,932 compared with 7 + 3 alone. With an incremental gain of 0.84 quality-adjusted life years (QALYs) with quizartinib + 7 + 3 induction vs. 7 + 3 alone, the incremental cost-effectiveness ratio for the addition of quizartinib to standard 7 + 3 was $344,039/QALY. Only an 87% reduction in the average wholesale price of quizartinib or omitting quizartinib continuation therapy after completion of consolidation therapy and allogeneic hematopoietic cell transplant would make quizartinib a cost-effective option. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
